Keros Therapeutics
Market Cap
US$1.7b
Last Updated
2021/01/16 00:19 UTC
Data Sources
Company Financials +
Executive Summary
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. More Details
Risk Analysis
Earnings are forecast to decline by an average of 31.2% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Keros Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KROS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: KROS's weekly volatility (9%) has been stable over the past year.
Market Performance
7 Day Return
0.9%
KROS
3.5%
US Biotechs
-0.9%
US Market
1 Year Return
n/a
KROS
36.8%
US Biotechs
19.6%
US Market
Return vs Industry: Insufficient data to determine how KROS performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KROS performed against the US Market.
Shareholder returns
| KROS | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.9% | 3.5% | -0.9% |
| 30 Day | -8.9% | 6.0% | 3.0% |
| 90 Day | 38.5% | 19.2% | 11.5% |
| 1 Year | n/a | 39.1%36.8% | 22.3%19.6% |
| 3 Year | n/a | 30.5%23.6% | 45.3%35.7% |
| 5 Year | n/a | 43.7%32.8% | 124.8%99.9% |
Long-Term Price Volatility Vs. Market
How volatile is Keros Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?3 months ago | Simply Wall St
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth5 months ago | Simply Wall St
Need To Know: Keros Therapeutics, Inc. (NASDAQ:KROS) Insiders Have Been Buying SharesValuation
Is Keros Therapeutics undervalued compared to its fair value and its price relative to the market?
11.05x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KROS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KROS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KROS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: KROS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KROS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KROS is overvalued based on its PB Ratio (11.1x) compared to the US Biotechs industry average (4.3x).
Next Steps
Future Growth
How is Keros Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
-31.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KROS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KROS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KROS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KROS is forecast to have no revenue next year.
High Growth Revenue: KROS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KROS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Keros Therapeutics performed over the past 5 years?
-247.4%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: KROS is currently unprofitable.
Growing Profit Margin: KROS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KROS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KROS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KROS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: KROS has a negative Return on Equity (-28.63%), as it is currently unprofitable.
Next Steps
Financial Health
How is Keros Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: KROS's short term assets ($136.4M) exceed its short term liabilities ($6.8M).
Long Term Liabilities: KROS's short term assets ($136.4M) exceed its long term liabilities ($663.0K).
Debt to Equity History and Analysis
Debt Level: KROS is debt free.
Reducing Debt: KROS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KROS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KROS has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 109.1% each year.
Next Steps
Dividend
What is Keros Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KROS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KROS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KROS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KROS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KROS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
Jas Seehra (65 yo)
no data
Tenure
US$694,519
Compensation
Dr. Jasbir Seehra, also known as Jas, Ph.D., has been Chief Executive Officer of Keros Therapeutics Inc., since 2016 and serves as its President, Treasurer and Secretary and has been its Director since Dec...
CEO Compensation Analysis
Compensation vs Market: Jas's total compensation ($USD694.52K) is below average for companies of similar size in the US market ($USD3.85M).
Compensation vs Earnings: Insufficient data to compare Jas's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$694.52k | 1.05% $ 17.5m | |
| Chief Scientific Officer | 1.58yrs | US$414.29k | 0.12% $ 2.0m | |
| Chief Medical Officer | 1.33yrs | US$201.91k | 0.11% $ 1.8m | |
| Chief Financial Officer | 0.92yr | no data | no data |
1.3yrs
Average Tenure
52yo
Average Age
Experienced Management: KROS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$694.52k | 1.05% $ 17.5m | |
| Independent Director | 0.83yr | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Independent Director | 4.75yrs | no data | no data | |
| Director | 0.083yr | no data | no data | |
| Independent Chairman of the Board | 4.75yrs | no data | no data | |
| Independent Director | 0.83yr | no data | 0.018% $ 304.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.0yrs
Average Tenure
57yo
Average Age
Experienced Board: KROS's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: KROS only recently listed within the past 12 months.
Top Shareholders
Company Information
Keros Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Keros Therapeutics, Inc.
- Ticker: KROS
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.659b
- Shares outstanding: 23.18m
- Website: https://www.kerostx.com
Number of Employees
Location
- Keros Therapeutics, Inc.
- 99 Hayden Avenue
- Suite 120
- Lexington
- Massachusetts
- 2421
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| KROS | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Apr 2020 |
Biography
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculos...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/16 00:19 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.